Clinical Trials Logo

Advanced Malignancies clinical trials

View clinical trials related to Advanced Malignancies.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05359692 Withdrawn - Clinical trials for Advanced Malignancies

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, efficacy, PK and pharmacodynamics of INCAGN01876 when given in combination with retifanlimab. The study will consist of 2 parts: a safety lead-in part (Part 1) followed by a dose expansion part (Part 2).

NCT ID: NCT05245916 Withdrawn - Clinical trials for Advanced Malignancies

IBI397 or Combination Therapies in Patients With Advanced Malignancies

Start date: April 14, 2022
Phase: Phase 1
Study type: Interventional

The primary objective of this phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBI397 or its Combination Therapies in Patients with Advanced Malignancies

NCT ID: NCT02520245 Withdrawn - Clinical trials for Advanced Malignancies

Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

Start date: August 2015
Phase: Phase 1
Study type: Interventional

This study has been designed to collect long-term follow-up information for patients who received REGN2810 in other clinical studies and to allow re-treatment for eligible patients.